Equities research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO – Get Free Report) in a report released on Wednesday. The brokerage set a “hold” rating on the ...

PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...

D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin ...

CytoSorbents (NASDAQ:CTSO) has announced preliminary Q4 and full-year 2024 financial results. The company estimates Q4 product revenue between $9.0 million-$9.2 million vs. consensus of $9.45M ...

PRINCETON, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...

This was corrected on 01/05/2025 at 1:03 AM. The revised post deletes Q4 and FY24 product revenue consensus ...

(RTTNews) - Critical care company CytoSorbents Corp. (CTSO) announced Friday preliminary fourth-quarter results, expecting 22 percent to 25 percent growth in product revenue, while product gross ...

PRINCETON, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...